Trial Profile
A Cost-Effectiveness Analysis of Telaprevir Versus Boceprevir in the Treatment of Hepatitis C: a Greek National Health System Perspective
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2015
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Telaprevir (Primary) ; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms ADVANCE; REALIZE; RESPOND-2; SPRINT-2
- Sponsors Merck Sharp & Dohme
- 14 Nov 2012 New trial record
- 07 Nov 2012 Results presented at the 15th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.